Literature DB >> 28331953

Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline.

Nare Torosyan1, Kelsey Mason1, Magnus Dahlbom1, Daniel H S Silverman2.   

Abstract

PURPOSE: The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI).
METHODS: Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer's Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer's disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores. PET images were analyzed using clinically routine brain quantification software. A dementia prognosis index (DPI), derived from a ratio of uptake values in regions of interest known to be hypometabolic in Alzheimer's disease to regions known to be stable, was generated for each baseline FDG-PET scan. The DPI was correlated with change in scores on the neuropsychological examinations to examine the predictive value of baseline FDG-PET.
RESULTS: DPI powerfully predicted rate of functional decline among MCI patients (t = 5.75, p < 1.0E-8) and pooled N + MCI patient groups (t = 7.02, p < 1.0E-11). Rate of cognitive decline on MMSE was also predicted by the DPI among MCI (t = 6.96, p < 1.0E-10) and pooled N + MCI (t = 8.78, p < 5.0E-16). Rate of cognitive decline on ADAS-cog was powerfully predicted by the DPI alone among N (p < 0.001), MCI (t = 6.46, p < 1.0E-9) and for pooled N + MCI (t = 8.85, p = 1.1E-16).
CONCLUSIONS: These findings suggest that an index, derivable from automated regional analysis of brain PET scans, can be used to help predict rates of functional and cognitive deterioration in the years following baseline PET.

Entities:  

Keywords:  Cognitive decline; Dementia; FDG; Functional decline; MCI; PET

Mesh:

Substances:

Year:  2017        PMID: 28331953     DOI: 10.1007/s00259-017-3634-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

2.  On telling the truth to patients with dementia.

Authors:  M Marzanski
Journal:  West J Med       Date:  2000-11

3.  Do older adults presenting with memory complaints wish to be told if later diagnosed with Alzheimer's disease?

Authors:  Paul Elson
Journal:  Int J Geriatr Psychiatry       Date:  2006-05       Impact factor: 3.485

4.  2015 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2015-03       Impact factor: 21.566

Review 5.  Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.

Authors:  S Zhang; D Han; X Tan; J Feng; Y Guo; Y Ding
Journal:  Int J Clin Pract       Date:  2012-02       Impact factor: 2.503

6.  Progression of mild cognitive impairment to dementia: a challenge to current thinking.

Authors:  Anja Busse; Matthias C Angermeyer; Steffi G Riedel-Heller
Journal:  Br J Psychiatry       Date:  2006-11       Impact factor: 9.319

Review 7.  Advances in the development of tau PET radiotracers and their clinical applications.

Authors:  Nobuyuki Okamura; Ryuichi Harada; Katsutoshi Furukawa; Shozo Furumoto; Tetsuro Tago; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo
Journal:  Ageing Res Rev       Date:  2016-01-21       Impact factor: 10.895

8.  Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.

Authors:  Chiara Cerami; Pasquale Anthony Della Rosa; Giuseppe Magnani; Roberto Santangelo; Alessandra Marcone; Stefano F Cappa; Daniela Perani
Journal:  Neuroimage Clin       Date:  2014-12-05       Impact factor: 4.881

9.  Early indications of future cognitive decline: stable versus declining controls.

Authors:  Angela Rizk-Jackson; Philip Insel; Ronald Petersen; Paul Aisen; Clifford Jack; Michael Weiner
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects.

Authors:  Michael Ewers; Matthias Brendel; Angela Rizk-Jackson; Axel Rominger; Peter Bartenstein; Norbert Schuff; Michael W Weiner
Journal:  Neuroimage Clin       Date:  2013-11-04       Impact factor: 4.881

View more
  4 in total

1.  18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.

Authors:  Silvia Morbelli; Matteo Bauckneht; Dario Arnaldi; Agnese Picco; Matteo Pardini; Andrea Brugnolo; Ambra Buschiazzo; Marco Pagani; Nicola Girtler; Alberto Nieri; Andrea Chincarini; Fabrizio De Carli; Gianmario Sambuceti; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-07       Impact factor: 9.236

Review 2.  The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review.

Authors:  Jacqueline K Kueper; Mark Speechley; Manuel Montero-Odasso
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Authors:  Tharick A Pascoal; Sulantha Mathotaarachchi; Monica Shin; Ah Yeon Park; Sara Mohades; Andrea L Benedet; Min Su Kang; Gassan Massarweh; Jean-Paul Soucy; Serge Gauthier; Pedro Rosa-Neto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-02       Impact factor: 9.236

4.  Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).

Authors:  Matteo Bauckneht; Andrea Chincarini; Roberta Piva; Dario Arnaldi; Nicola Girtler; Federico Massa; Matteo Pardini; Matteo Grazzini; Hulya Efeturk; Marco Pagani; Gianmario Sambuceti; Flavio Nobili; Silvia Morbelli
Journal:  Alzheimers Res Ther       Date:  2018-04-03       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.